White Papers

Inpharmation is founded on using pharma-validated evidence-based methods

All Inpharmation’s pricing, forecasting, and demand market research solutions are based on years of development, calibration, and research.

Below you can browse a selection of interesting white papers. Many of these papers provide head-to-head validation and evidence as to why Inpharmation’s solutions are best placed to provide you with the most reliable insights.

To receive a full free copy of any white paper:

  1. Click on the white paper that most interests you.
  2. Submit a request via the download instructions.

What impact is artificial intelligence having on pharma pricing and forecasting?

Artificial intelligence is having a profound effect in pharma R&D. For example, it is making wonderfully accurate predictions of protein folding. Why is it not having a similarly revolutionary impact on demand and price forecasting? This article explains why.

Read More

When payers around the world behave as if they use QALYs

Many payers do not use QALYs when making pricing decisions. Nevertheless, they behave as if they do. This article explains why the best predictive models often do not reflect reality. We use, as an example, the usefulness of QALYs in predicting payer decisions.

Read More

Is there a valid approach to converting preference scores to market shares?

Market research agencies often advise that the preference scores that come out of conjoint studies must not be used for making market share forecasts. Preference scores are, in fact, very useful for market share forecasting – when they are correctly transformed.  

Read More

Are ICER publications having an impact on drug price acceptability in the US?

The Institute for Clinical and Economic Review (ICER) is a US lobby group that looks at the clinical benefit of value-added drugs and recommends “cost-effective” prices. Their definition of cost-effectiveness is not a hard barrier, such as the one used by NICE in the UK, but is a range of thresholds, the highest of which […]

Read More

An objective look at patient allocation exercises and a more accurate alternative

Many forecasts are guided by so-called “patient allocation” exercises. Here, prescribers are asked to predict how many of their patients they would treat with each current product and (usually) one novel product—whose profile they are shown. This seems a sensible approach. However, you must distinguish between research questions (what you want to know) and survey […]

Read More

Multi-criteria decision making analysis for pricing pharmaceuticals

Multi-criteria decision analysis (MCDA) is occasionally used as a tool to predict the price opportunity of new pharmaceuticals. This white paper explains the advantages and disadvantages of the approach.

Read More

Scroll Top